Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD‐driven salvage approach.

Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach Patients with Mol-relapse defined according to the aforementioned criteria progressed to overt Haem-relapse within 3 months from the third BM sample (range 0-5-3); no patient experienced haematological relapse before fulfilling Mol-relapse criteria. GLO:1XW/15sep19:bjh16116-fig-0001.jpg PHOTO (COLOR): Pre- and post-therapy disease burden in patient treated for MRD relapse compared to patients treated for haematological relapse. [Extracted from the article]